Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

63.24EUR
8:58pm IST
Change (% chg)

€-0.28 (-0.44%)
Prev Close
€63.52
Open
€63.26
Day's High
€63.68
Day's Low
€62.78
Volume
562,719
Avg. Vol
1,587,232
52-wk High
€80.07
52-wk Low
€60.15

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €39,028.29
Shares Outstanding(Mil.): 554.54
Dividend: 0.62
Yield (%): 0.88

Financials

Fresenius CFO backs acquisition course: Boersen-Zeitung

FRANKFURT German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying.

07 Jan 2018

Fresenius CFO backs acquisition course -Boersen-Zeitung

FRANKFURT, Jan 7 German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying.

07 Jan 2018

BRIEF-Fresenius says US Tax Reform ‍results In One-Time Book Gain Of about 90 mln euros

* ‍NEW US TAX LEGISLATION TRIGGERS REVALUATION OF DEFERRED TAX LIABILITIES​

23 Dec 2017

Fresenius sees book gain of 90 mln euros from U.S. tax reform in 2017

FRANKFURT, Dec 22 German healthcare group Fresenius said late on Friday a U.S. tax reform would lead to a one-time book gain of around 90 million euros ($107 million) affecting its 2017 net income.

23 Dec 2017

Deals of the day-Mergers and acquisitions

Nov 22 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:

23 Nov 2017

Fresenius says on track to increase dividend again next year

FRANKFURT, Nov 21 German healthcare group Fresenius SE is well on its way to further increase its annual dividend next year, reflecting the prospect of earnings growth in 2017, its chief executive said.

21 Nov 2017

Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

27 Oct 2017

Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

27 Oct 2017

UPDATE 3-Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON, Oct 26 The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

27 Oct 2017

Senvest Management shorting drug stocks Insys, Akorn, Fresenius

TEL AVIV, Oct 3 New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday,

03 Oct 2017

Earnings vs. Estimates